no serum from this individual. Evidence about the effects of other mutations and polymorphisms in this region suggests that a functional effect through disruption of interaction with FI is likely: the protective allele of rs800292 (62I in SCR1) results in enhanced FI cofactor activity and reduced risk of AMD. A mutation of a conserved amino acid in SCR1, G69E, has also been reported in association with AMD (Raychaudhuri et al. 2011) . A mutation of CFH (P503H) which is strongly associated with AMD in Amish people alters the equivalent amino acid in SCR8 as that which P139A alters in SCR2 (Hoffman et al. 2014) .
It is possible that rare mutations of CFH SCRs 1-4 are relatively common in people with early-onset or severe AMD. We would expect to find clustering of AMD cases in families that carry these mutations. The increasing use of massively parallel sequencing in other AMD research DNA collections will show whether this is the case. Developing real-world applications for advancing the understanding of inherited diseases is a challenge, but eye diseases continue to be prime targets for 'personalized medicine' based on the best knowledge of disease processes and individual risk. A retrospective review of electronic patients' charts at the Department of Ophthalmology, County Hospital Council of V€ astmanland during the period 1 January 2011 until 31 December 2012 was performed. The study followed the Tenets of the Declaration of Helsinki and was approved by the Regional Ethical Review Board at Uppsala University.
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The ICD-10 (International Statistical Classification of Diseases and Related Health Problems) code keratitis (H16) was used in the search of patients' charts. Cases with corneal infiltrates (n = 159), cases with corneal epithelial defects combined with intra-ocular inflammation (n = 7) and clinical bacterial keratitis (n = 6) were included in the review. All cases included had received antibiotic treatment. In all, the study comprised 172 cases. Follow-up data were available in 120 cases, whereas final visual acuity (VA) was available and obtained in 99 cases.
Seven patients (4%) had bilateral keratitis. Gender distribution was close to 1:1 (88 women and 84 men). The age of the patients ranged from 0 to 96 years. Most patients were aged 20-39 years (40%) and 40-59 years (28%). Mean duration of subjective symptoms before diagnosis was 2.7 days (SD 2.4).
A predisposing factor was identified in 71% of the cases. Contact lens wear was the most frequent risk factor (53%) followed by corneal trauma (11%) and corneal pathology (5%). In 58% of cases, a culture was taken. Out of 106 cultures taken, 97 were conjunctival smears, seven were corneal scrapings, and two were from contact lenses. In 20 cultures (71% of corneal scrapings and 13% of conjunctival smears), a causative agent/bacteria could be identified (Table 1) .
In total, 93% of the cases were treated empirically with topical levofloxacin. No 
Staphylococcus aureus
1 difference in choice of antibiotic treatment was seen between age groups. The antibiotic was given as monotherapy (66%) or in combination with another antibiotic (34%). Cycloplegics were given in 42 cases, and topical corticosteroid was added during follow-up in 24 cases. Surgical adjunctive therapy was provided in seven cases: crosslinking (4), amniotic membrane transplantation (3), conjunctival flap (1) and evisceration (1). Two cases had both an amniotic membrane transplantation and underwent cross-linking. Four patients were hospitalized due to lack of treatment response, insufficient compliance or threatening corneal perforation. A causative agent was identified in three cases that required surgical therapy. In the eviscerated eye, staphylococcus aureus was identified in a conjunctival smear. Initial VA ranged from amaurosis to Snellen 30/20. In 90% of cases, preserved or improved VA was observed at the last follow-up visit. An improvement in VA was seen in three of the four patients that underwent crosslinking.
In conclusion, the epidemiologic data in this study are in line with previous reports (Schaefer et al. 2001; Bourcier et al. 2003) . The majority of cases were successfully treated empirically. Overall, observed clinical care adhered to the AAO recommendations (AAO 2013) including choice of firstin-line antibiotic. However, corneal scrapings for culture could be taken more frequently, especially in cases of severe keratitis. Editor, A nti-vascular endothelial growth factor (VEGF) therapy has been shown to stabilize and improve vision in eyes treated for neovascular age-related macular degeneration (NVAMD) (Schimdt-Erfurth et al. 2014 ), but none of the patients in the clinical trials were noted to have a history of prior pars plana vitrectomy (PPV); and the clinical question often arises whether intravitreal anti-VEGF therapy would be less effective in vitrectomized eyes. Previous studies of intravitreal medications have shown that clearance rates are faster after previous vitrectomy (Gisladottir et al. 2009 ). Therefore, intravitreal anti-VEGF therapy could potentially be less effective in vitrectomized eyes due to decreased viscosity and increased fluid currents leading to a decreased half-life and access to receptors (Christoforidis et al. 2013) . We report an observational case series of four patients who were previously vitrectomized unilaterally, subsequently developed treatment-na€ ıve NVAMD and were treated with aflibercept to adequately control their disease.
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We retrospectively reviewed four patients (three female) who developed NVAMD after prior PPV, followed for 23.8 AE 0.5 months (meanAEstandard deviation) and were treated with intravitreal aflibercept (0.5 mg/0.5 ml, Eylea; Regeneron, Tarrytown, NY) pro re nata (PRN) after an initial loading regimen of 3 monthly injections based on spectral-domain optical coherence tomography (SD-OCT) and clinical findings of recurrence of disease, defined as the presence of cystoid macular oedema or subretinal fluid on SD-OCT or haemorrhage on fundoscopy seen between January 2012 and January 2015 by a single physician (S.C.). Their clinical histories, best correct visual acuity (BCVA, in log-MAR) and SD-OCT findings including central foveal thickness (CFT) and initial lesion type are summarized in Table 1 .
Mean age was 85 AE 5.4 years (range 81-93). On average, patients required 7.9 AE 1.0 aflibercept injections/year (range 6.8-8.7) to avoid recurrence. While on aflibercept treatment, BCVA improved from 0.88 AE 0.74 (range 0.40-2.0) to 0.64 AE 0.91 (range 0.10-2.0) at 2 years with an average improvement of 0.24 AE 0.18 (range 0.0-0.43). CFT improved from 449.5 AE 82.0 lm (range 363-558) to 323.8 AE 89.2 lm (range 195-295) at 2 years with an average decrease of 125.8 AE 96.0 lm (range 27-225). There was a clinical and anatomical improvement except in Case 4, where atrophy developed in the macula.
Case 1 of an 81-year-old female who had undergone left eye (OS) PPV for a macular pucker 10 years prior illustrates a patient who received bilateral aflibercept injections for treatmentna€ ıve NVAMD. At diagnosis OS, SD-OCT demonstrated a mature type 3 (retinal angiomatous proliferation) and she received aflibercept at a rate of 8.7 injections/year OS. Five months after diagnosis OS, her right eye (OD) developed a type 1 choroidal neovascularization (sub-retinal pigment epithelium, CNV) and required an average of 4.7 injections/year OD. Interestingly, the average frequency of PRN injections required for disease control in
